KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Cash & Equivalents (2016 - 2025)

Idexx Laboratories has reported Cash & Equivalents over the past 17 years, most recently at $180.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $180.1 million for Q4 2025, down 37.53% from a year ago — trailing twelve months through Dec 2025 was $180.1 million (down 37.53% YoY), and the annual figure for FY2025 was $180.1 million, down 37.53%.
  • Cash & Equivalents for Q4 2025 was $180.1 million at Idexx Laboratories, down from $208.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IDXX hit a ceiling of $453.9 million in Q4 2023 and a floor of $99.2 million in Q3 2022.
  • Median Cash & Equivalents over the past 5 years was $192.3 million (2022), compared with a mean of $227.3 million.
  • Peak annual rise in Cash & Equivalents hit 331.43% in 2021, while the deepest fall reached 62.37% in 2021.
  • Idexx Laboratories' Cash & Equivalents stood at $144.5 million in 2021, then decreased by 22.09% to $112.5 million in 2022, then soared by 303.33% to $453.9 million in 2023, then tumbled by 36.5% to $288.3 million in 2024, then tumbled by 37.53% to $180.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $180.1 million (Q4 2025), $208.2 million (Q3 2025), and $164.6 million (Q2 2025) per Business Quant data.